Clinical Trial Update: Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating acalabrutinib in patients with chronic lymphocytic leukemia and mantle cell lymphoma after allogeneic stem cell transplantation, with c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Graft-versus-host Disease
• Mantle Cell Lymphoma

Drugs mentioned

• Acalabrutinib (acalabrutinib)

Snippet

Sponsor: Polish Lymphoma Research Group | Conditions: Chronic Lymphocytic Leukemia, Chronic Graft-versus-host-disease | Phase 2 | Status: COMPLETED